
A new non-invasive device that uses alternating electrical fields to blast brain tumors and kill cancer cells before they can multiply has received the backing of a US Food and Drug Administration (FDA) panel, although two panel members abstained from voting because of concerns that while trials showed the device was safe, it did not appear to be effective. The main argument in support of the device appears to be that it offers patients a higher quality of life, and is not necessarily about longer survival, where its effect appears to be minimal.
Brain Tumor Blaster Gets FDA Panel Support
Patients who attended the panel hearing last week urged members to recommend FDA approval. The Neurological Devices Panel of the Medical Devices Advisory...